Posted by Michael Wonder on 02 Feb 2021
If 2021 is to be the year of U.S. drug price controls, how should biopharma companies respond?
2 February 2021 - As the Biden administration assumes leadership in Washington and former President Donald Trump’s most favoured nation ruling has been halted by a federal judge, drug price controls don’t feel imminent.
Though this should provide some relief to the R&D based biopharmaceutical industry, the relief may be short lived.
